John Heymach, MD, PhD
Advertisement
Articles by John Heymach, MD, PhD
John Heymach, MD, reviews the evolving treatment landscape of EGFR+ metastatic non-small cell lung cancer.
John Heymach, MD, PhD, chair of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, discusses the characteristics of three more KRAS subsets in lung cancer, which researchers discovered in a recent study.
Advertisement
Latest Updated Articles
Improved Outcomes for Patients With EGFR+ NSCLCMay 21st 2020
Molecular Testing for Newly Diagnosed NSCLCMay 21st 2020
Repeat Testing at Progression of EGFR+ NSCLCMay 21st 2020
Treatment Options for EGFR+ NSCLCMay 21st 2020
Changing Landscape of EGFR+ mNSCLCMay 21st 2020
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Behind the FDA Approval: Isatuximab On-Body Injector Supports ‘Patient-Centric’ Priorities in Multiple Myeloma
2
Safusidenib Shows Durable Responses in IDH1-Mutant Glioma at 3-Year Follow-Up
3
CheckMate 9LA Data Push Toward Dual Checkpoint Blockade in PD-L1–Negative NSCLC
4
Thoracic Radiotherapy Added to Atezolizumab Raised Toxicity in SCLC
5